Dermatological Drugs Industry in 2012-2022 Discussed by Visiongain

14 Mar 2012 • by Natalie Aster

The pharma industry has potential for improved treatments and increased revenues from dermatological agents. The R&D pipeline is strong.

New Visiongain's report ”Dermatological Drugs: World Market Prospects 2012-2022” shows potential revenues to 2022, with data, forecasts and discussions.

This study assesses drugs to treat human skin disorders. Sales predictions at world market, therapeutic submarket, product and national levels to 2022 are revealed. The report gives business research and analysis with many sales forecasts.

Potential revenues are discussed for:

• Dermatitis 
• Psoriasis 
• Acne 
• Infectious skin diseases 
• Miscellaneous dermatologics.

Report Details:

Dermatological Drugs: World Market Prospects 2012-2022
Published: January, 2012
Pages: 168
Price: US$ 2.642,00

The report discusses GSK, Galderma, Amgen, Abbott, J&J and other pharmaceutical companies, assessing prospects of the industry and market. Many commercial opportunities in treating skin disorders remain, including increased revenues.

Visiongain's study provides data, analysis and opinion aiming to benefit research, calculations, meetings and presentations.

More information can be found in the report “Dermatological Drugs: World Market Prospects 2012-2022” by Visiongain.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com